Chengdu Kanghong Pharmaceutical Group (002773): Combixip steady growth, focusing on the progress of ophthalmic innovative drugs.

Investment highlights: Event: The company released the third quarter report of 2024, achieving revenue of 3.41 billion yuan in the first three quarters of 2024 (+13.8% year-on-year), attributable net income of 0.97 billion yuan (+18.0% year-on-year), net income excluding non-recurring items.

华福证券Oct 27 12:51

Kanghong Pharmaceutical: Report for the third quarter of 2024

SZSIOct 25 00:00 · Announcements

Express News | Chengdu Kanghong Pharmaceutical Group: Net income in the third quarter decreased by 6.18% year-on-year.

BreakingsOct 24 18:38

Express News | Chengdu Kanghong Pharmaceutical Group: The company has received the pharmaceutical clinical trial approval notification.

BreakingsOct 18 18:27

Express News | chengdu kanghong pharmaceutical group: The clinical trial application for KH629 tablets has been approved.

BreakingsOct 18 18:26

Express News | Chengdu Kanghong Pharmaceutical Group: Vice President He Xiaorong resigns for personal reasons.

BreakingsSep 19 18:03